
Toshiro Shinke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1124792/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography Studies. Journal of the American College of Cardiology, 2012, 59, 1058-1072.	2.8	1,530
2	Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. European Heart Journal, 2007, 28, 961-967.	2.2	320
3	Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2009, 2, 459-466.	2.9	128
4	Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nature Reviews Cardiology, 2022, 19, 684-703.	13.7	106
5	β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes. Biochemical and Biophysical Research Communications, 2016, 475, 322-328.	2.1	79
6	Effect of Daily Glucose Fluctuation on Coronary Plaque Vulnerability in Patients Pre-Treated With Lipid-Lowering Therapy. JACC: Cardiovascular Interventions, 2015, 8, 800-811.	2.9	64
7	Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart, 2011, 97, 1379-1384.	2.9	59
8	Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel. Circulation Journal, 2012, 76, 2348-2355.	1.6	43
9	Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography. Cardiovascular Diabetology, 2015, 14, 78.	6.8	40
10	Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography. Cardiovascular Diabetology, 2016, 15, 79.	6.8	36
11	Impact of CD14 ++ CD16 + monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients. Atherosclerosis, 2018, 269, 245-251.	0.8	32
12	Impact of CD14++CD16+ monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study. Cardiovascular Diabetology, 2017, 16, 96.	6.8	30
13	Impact of Stent Platform of Paclitaxel-Eluting Stents. Circulation Journal, 2012, 76, 1880-1888.	1.6	21
14	Duration of Hyperemia With Intracoronary Administration of Papaverine. Journal of the American Heart Association, 2021, 10, e018562.	3.7	19
15	Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation. Circulation Journal, 2014, 78, 1882-1890.	1.6	17
16	Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study. BMJ Open, 2020, 10, e028831.	1.9	17
17	Two-year vessel healing after everolimus-eluting stent implantation: Serial assessment by optical coherence tomography. Journal of Cardiology, 2015, 65, 298-304.	1.9	15
18	Serial Optical Coherence Tomography Evaluation at 6, 12, and 24 Months After Biolimus A9-Eluting Biodegradable Polymer-Coated Stent Implantation. Canadian Journal of Cardiology, 2015, 31, 980-988.	1.7	14

TOSHIRO SHINKE

#	Article	IF	CITATIONS
19	Impact of final kissing balloon inflation on vessel healing following drug-eluting stent implantation: Insight from the optical coherence tomography sub-study of the J-REVERSE trial. Journal of Cardiology, 2016, 68, 504-511.	1.9	13
20	Optical coherence tomography study of chronic-phase vessel healing after implantation of bare metal and paclitaxel-eluting self-expanding nitinol stents in the superficial femoral artery. Journal of Cardiology, 2016, 67, 424-429.	1.9	12
21	Comparison of the relationship between multiple parameters of glycemic variability and coronary plaque vulnerability assessed by virtual histology–intravascular ultrasound. Journal of Diabetes Investigation, 2018, 9, 610-615.	2.4	12
22	Two-year vascular responses to drug-eluting stents with biodegradable polymer versus durable polymer: An optical coherence tomography sub-study of the NEXT. Journal of Cardiology, 2017, 70, 530-536.	1.9	9
23	Coronary High-Intensity Plaques at T1-weighted MRI in Stable Coronary Artery Disease: Comparison with Near-Infrared Spectroscopy Intravascular US. Radiology, 2022, 302, 557-565.	7.3	9
24	A serial optical frequency-domain imaging study of early and late vascular responses to bioresorbable-polymer sirolimus-eluting stents for the treatment of acute myocardial infarction and stable coronary artery disease patients: results of the MECHANISM-ULTIMASTER study. Cardiovascular Intervention and Therapeutics, 2022, 37, 281-292.	2.3	8
25	Development, validation, and reproducibility of the pullback pressure gradient (PPG) derived from manual fractional flow reserve pullbacks. Catheterization and Cardiovascular Interventions, 2022, 99, 1518-1525.	1.7	8
26	Differences in Vessel Healing Between Sirolimus- and Everolimus-Eluting Stent Implantation for Bifurcation Lesions: The J-REVERSE Optical Coherence Tomography Substudy. Canadian Journal of Cardiology, 2016, 32, 384-390.	1.7	6
27	Favorable early vessel healing after everolimus-eluting stent implantation: 3-, 6-, and 12-month follow-up of optical coherence tomography. Journal of Cardiology, 2018, 72, 193-199.	1.9	6
28	The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial. BMC Cardiovascular Disorders, 2021, 21, 92.	1.7	6
29	Efficacy of optical frequency domain imaging in detecting peripheral artery disease: the result of a multi-center, open-label, single-arm study. Heart and Vessels, 2021, 36, 818-826.	1.2	6
30	Feasibility, Safety, and Long-Term Outcomes of Zero-Contrast Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. Circulation Journal, 2022, 86, 787-796.	1.6	6
31	Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipidâ€lowering therapy. Journal of Diabetes Investigation, 2021, 12, 1015-1024.	2.4	5
32	Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall) Tj ETQq0 0 0	rgBT /Ove 1.5	erlock 10 Tf 5 4
33	1777-1784. Clinical predictors for bradycardia and supraventricular tachycardia necessitating therapy in patients with unexplained syncope monitored by insertable cardiac monitor. Clinical Cardiology, 2021, 44, 683-691.	1.8	4
34	Effect of low-density lipoprotein cholesterol on the geometry of coronary bifurcation lesions and clinical outcomes of coronary interventions in the J-REVERSE registry. Cardiovascular Intervention and Therapeutics, 2018, 33, 360-371.	2.3	3
35	Acute myocardial infarction caused by persistent coronary spasm associated with high-grade macrophage accumulation. BMJ Case Reports, 2020, 13, e234502.	0.5	3
36	Reconstruction of an Extracardiac Aortocoronary Collateral and Simulation of Selective Angiography With Multidetector-Row Computed Tomography. Circulation, 2015, 131, e476-9.	1.6	2

TOSHIRO SHINKE

#	Article	IF	CITATIONS
37	Comparison of Everolimus- versus Sirolimus-eluting stents in the provisional Bifurcation stenting guided by intravascular ultrasound: mid-term results of the J-REVERSE registry. Cardiovascular Intervention and Therapeutics, 2016, 31, 1-12.	2.3	2
38	Comparison of serial optical coherence tomography imaging following aggressive stent expansion technique: insight from the MECHANISM study. International Journal of Cardiovascular Imaging, 2021, 37, 419-428.	1.5	2
39	Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. Journal of Cardiology, 2018, 72, 403-410.	1.9	1
40	Ultra-minimum contrast percutaneous coronary intervention for a patient with complex coronary artery disease and end-stage diabetic nephropathy. Journal of Cardiology Cases, 2021, 23, 290-293.	0.5	1
41	Hemodynamic changes during transcatheter atrial septal defect closure predict midterm heart failure deterioration in adults. Catheterization and Cardiovascular Interventions, 2021, 98, E715-E723.	1.7	1
42	Final 5-Year Results in Randomized Japanese Patients Implanted With a Thin-Strut, Bioabsorbable, Polymer-Coated, Everolimus-Eluting SYNERGY Stent (From the EVOLVE II Study). Circulation Reports, 2021, 3, 9-17.	1.0	1
43	Data on impact of monocytes and glucose fluctuation on plaque vulnerability in patients with coronary artery disease. Data in Brief, 2018, 18, 172-175.	1.0	0